$Tonix Pharmaceuticals (TNXP.US)$ Clearly more testing is ahead for TNX-801, but the technology behind it is rooted in the science of Edward Jenner's smallpox vaccine of the late 1700s, the only vaccine to successfully eradicate a contagious viral pathogen.
1
$Tonix Pharmaceuticals (TNXP.US)$ Tonix has successfully completed non-human primate studies showing protection from challenge with lethal doses of the Clade 1 monkeypox virus that is driving the new epidemic.
Clearly more testing is ahead for TNX-801, but the technology behind it is rooted in the science of Edward Jenner's smallpox vaccine of the late 1700s, the only vaccine to successfully eradicate a contagious viral pathogen.
Clearly more testing is ahead for TNX-801, but the technology behind it is rooted in the science of Edward Jenner's smallpox vaccine of the late 1700s, the only vaccine to successfully eradicate a contagious viral pathogen.
$Anew Medical (WENA.US)$ This key intellectual property asset was licensed on an exclusive worldwide basis by ANEW from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Barcelona, Spain. On March 4, 2024, the Company previously announced patent approval in China (CN108289933B) and is now approved in China Hong Kong (HK1259628A1) as well. ANEW plans to begin product development and expand their intellectual property portfolios into the Asi...
$Anew Medical (WENA.US)$ ANEW MEDICAL, INC. (NASDAQ:WENA) ("ANEW" or "the Company") a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders and specialty diagnostics, announces that is has been granted and issued a patent in Europe, EP3377091B1, for the use of ANEW's secreted Klotho gene sequence and gene delivery systems to be used in the treatment of diminished cognition, memory loss, dementia and other neurodeg...
$Anew Medical (WENA.US)$ ANEW MEDICAL Shares Are Trading Higher After the Company Announced the Grand T and Issuance of Patent Number HK1259628 for the Treatment of Neurodegenerative Diseases to Include Alzheimer's Disease, Parkinson's Disease and ALS
$Anew Medical (WENA.US)$ After 2, you can see 3.
Translated
$Anew Medical (WENA.US)$ ANEW MEDICAL, INC. Strengthens Intellectual Property Protection by Issuing a US Patent for an RNA Splicing Variant Secreted by the Human Klotho Gene for the Treatment of Neurodegenerative and Age-Related Diseases
(ANEW MEDICAL, INC. NASDAQ: WENA) has obtained a US patent number 12,036,268 because of the RNA splicing variant of the human Klotho gene it secretes, known as “s-KL.”
The patent strengthens ANEW's intellectual property protection in developing treatments for neurodegenerative and age-related diseases.
The Klotho gene, commonly known as an “anti-aging” gene, controls various brain and nervous system functions.
ANEW has exclusive global rights to develop and commercialize novel genetic methods for the treatment of diseases such as Alzheimer's, ALS, and Parkinson's disease.
The company's intellectual property portfolio has been licensed by the Autonomous University of Barcelona and the Catalan Institute of Advanced Studies. This US patent complements existing patents in Europe, China, and other Asian markets, and strengthens ANEW's global intellectual property position.
(ANEW MEDICAL, INC. NASDAQ: WENA) has obtained a US patent number 12,036,268 because of the RNA splicing variant of the human Klotho gene it secretes, known as “s-KL.”
The patent strengthens ANEW's intellectual property protection in developing treatments for neurodegenerative and age-related diseases.
The Klotho gene, commonly known as an “anti-aging” gene, controls various brain and nervous system functions.
ANEW has exclusive global rights to develop and commercialize novel genetic methods for the treatment of diseases such as Alzheimer's, ALS, and Parkinson's disease.
The company's intellectual property portfolio has been licensed by the Autonomous University of Barcelona and the Catalan Institute of Advanced Studies. This US patent complements existing patents in Europe, China, and other Asian markets, and strengthens ANEW's global intellectual property position.
Translated
$Anew Medical (WENA.US)$ ANEW MEDICAL Announced The Signing Of An Exclusive Worldwide License Agreement With Transfertech Sherbrooke Regarding Nanoject, A Needle-free, Freeze-dried Nanopowder Autoinjector For Medicines And Vaccines